Protocols

Important Disclaimer: The information below describes protocols reported in research studies and clinical trials. This is not personalized medical advice. Any clinical use of exosome joint injections should only be performed by qualified healthcare professionals as part of approved clinical trials or studies, following proper regulatory oversight.

Based on available literature, standardized protocols for exosome joint injection are still being established through ongoing clinical trials. The evidence base remains limited, with most studies in early-phase trials.

Current Clinical Trial Approaches

Several active clinical trials are investigating intra-articular exosome injection protocols:

Early-Phase Trials:

Studies focusing on knee osteoarthritis using MSC-derived exosomes (NCT05060107, NCT06431152)
Phase 2 investigation for degenerative meniscal injury (NCT05261360)
Research examining umbilical cord-derived MSC exosomes (NCT06466850)

Delivery Methods Under Investigation

Recent research has explored various delivery approaches beyond direct injection:

Enhanced Delivery Systems:

Thermosensitive hydrogel carriers combined with MSC-derived exosomes
ROS-responsive hydrogel systems for sustained release
Microfluidic-produced hyaluronic acid microspheres incorporating exosomes
Combined approaches using exosomes with hyaluronic acid

Current Research Limitations

The literature reveals significant gaps in standardized protocols:

Dosing: Specific dosing regimens are not clearly established in the available evidence
Frequency: Administration intervals vary across studies and are not yet standardized
Source variability: Studies use exosomes from different cell sources (bone marrow MSCs, umbilical cord MSCs, platelet-rich plasma)
Preparation methods: Standardized exosome isolation and purification protocols are still being refined

Clinical Status

Most exosome joint injection protocols remain investigational. The field is rapidly evolving, with studies primarily in Phase 1 and early Phase 2 trials. Standardized clinical protocols for routine use have not yet been established.

Healthcare providers considering exosome therapies should refer to current clinical trial protocols and regulatory guidelines, as this remains an experimental treatment approach requiring proper oversight and patient consent.

Exosome Joint Injection

Member access required